Manufacturer record
Transflexjawaharnagar: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Transflexjawaharnagar (Chhattisgarh) were declared Not of Standard Quality between May 2024 and May 2024. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
1 record linked to Transflexjawaharnagar in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Disinfectants, Surgical Spirit BP | SS-053011Mfg 2023-05 · Exp 2025-04 | MISBRANDED As per rule R.124 the drug is included in the current edition of Indian Pharmacopoiea 2022. Hence standards shall be of those as specified in Indian Pharmacopoiea 2022. But the subject drug Surgical spirit bears the letters B.P after the drug name instead of IP. As per rule 96 and 104 as the drug shall be in accordance with standards set out in Indian Pharmaopoiea, the name of the drug surgical spirit shall be followed by the letters IP. As the subject drug is not confirming to the said labelling requirements the drug shall be deemed to be Misbranded as per section 17.Misbranded | State Lab Drugs Control Laboratory, TelanganaState lab | May 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.